ENA presentation webcasts
View ENA presentation webcasts here
Friday 2 December
Advanced soft tissue sarcomas respond to a combination of a new and an existing anti-cancer drug
Munich, Germany: Researchers working to find effective treatments for soft tissue sarcomas have discovered that combining a new anti-cancer drug with an existing one kills cancer cells not only in the laboratory but also in the first two patients treated with it, leading to unusually long-lasting periods without the disease progressing.
Phase I trial shows that a drug that inhibits the Notch signalling process is active in a range of advanced cancers
Munich, Germany: A new anti-cancer drug that inhibits a key cell signalling process involved in many different cancers has shown that it is capable of stopping the progression of cancer and shrinking tumours. Importantly, it has been able to do this in rare cancers that are less well-studied such as adenoid cystic carcinoma.
Thursday 1 December
How highs and lows in testosterone levels ‘shock’ prostate cancer cells to death
Munich, Germany: A strategy of alternately flooding and starving the body of testosterone is producing good results in patients who have metastatic prostate cancer that is resistant to treatment by chemical or surgical castration, according to new findings.
Promising results from new drug combination in patients with advanced solid tumours
Munich, Germany: An experimental drug called TAS-114, which has the potential to increase the anti-cancer effects of chemotherapy without increasing adverse side effects, has shown promising results in patients with hard-to-treat cancers in a phase I clinical trial.
Revolution in our understanding of cancer’ sees dramatic responses to targeted treatments in advanced cancers
Results from three ground-breaking studies show early benefit to patients
Munich, Germany: The “revolution in the understanding of cancer at the molecular level” has led to dramatic responses in cancer patients to new therapies that are targeted precisely at their particular type of tumours, according to an expert.
Wednesday 30 November
Anti-cancer drug, CB-839, in combination with everolimus, stops tumours growing in patients with advanced kidney cancer
Munich, Germany: The first drug to target a key enzyme that cancer cells need to keep them alive has shown that it is effective in controlling disease in patients with advanced kidney cancer when it is used in combination with another anti-cancer drug, everolimus.
Tuesday 29 November
Make funding for cancer research a global priority, say European and US organisations
Munich, Germany: The European Organisation for Research and Treatment of Cancer (EORTC) and the American Association for Cancer Research (AACR) are calling on policymakers and leaders throughout the world to provide robust and sustained funding for cancer research.